Gainers
- Baudax Bio, Inc. BXRX shares surged 59.7% to $5.03 after the company announced the outcome of its first interim analysis in a Phase II trial of BX1000 for neuromuscular blockade in patients undergoing elective surgery.
- bioAffinity Technologies, Inc. BIAF gained 46% to $2.34 after the company announed the publication of results of its clinical trial in peer-reviewed journal Respiratory Research.
- Axcella Health Inc. AXLA shares jumped 36% to $0.59 after the company reported regulatory path to registration of AXA1125 for long COVID-19 fatigue.
- Grom Social Enterprises, Inc. GROM gained 34.9% to $2.9950.
- Inhibikase Therapeutics, Inc. IKT jumped 22.4% to $0.9190.
- Ontrak, Inc. OTRK gained 21% to $1.01.
- Allied Healthcare Products, Inc. AHPI gained 18.6% to $1.27.
- Helbiz, Inc. HLBZ rose 18.5% to $0.5055 after the company announced over 1300 pre-orders generating over $2.2 million in future sales.
- Draganfly Inc. DPRO jumped 18.2% to $1.7264. HC Wainwright & Co. recently maintained Draganfly with a Buy and raised the price target from $1.5 to $2.
- WiSA Technologies, Inc. WISA jumped 16.2% to $0.1858.
- Novo Integrated Sciences, Inc. NVOS rose 16% to $0.1439.
- Intelligent Bio Solutions Inc. INBS shares gained 14.5% to $1.17. Intelligent Bio Solutions shares jumped 281% on Monday after the company announced it successfully completed the review of results from Milestone 7, a phase of its biosensor platform development.
- Genius Group Limited GNS jumped 13% to $5.32. For the full year of 2023, the company expects annual revenue to be between $48 million and $52 million and expects the number of students and users to be between 5.7 million and 6 million.
- Armata Pharmaceuticals, Inc. ARMP surged 11.8% to $3.0085.
- Bed Bath & Beyond Inc. BBBY rose 11.4% to $3.2899. The stock has seen increased volatility over the last two weeks as the embattled retailer considers strategic alternatives, including potential bankruptcy.
- CymaBay Therapeutics, Inc. CBAY gained 11.2% to $7.34. The company priced a public offering of common stock and pre-funded warrants at $7 per share and $6.999 per warrant.
- Evolve Transition Infrastructure LP SNMP rose 11.1% to $0.2555 after surging 53% on Monday.
- Compass Therapeutics, Inc. CMPX shares gained 10.8% to $4.22. Compass Therapeutics recently said its combo therapy showed around 38% overall response rate in pretreated biliary tract cancer patients.
- Concrete Pumping Holdings, Inc. BBCP jumped 10.2% to $7.18 after the company posted upbeat Q4 results.
- Ainos, Inc. AIMD gained 9.9% to $0.80.
- Ardmore Shipping Corporation ASC rose 6.4% to $13.82.
Losers
- Satixfy Communications Ltd. SATX shares dipped 64% to $2.60. SatixFy recently appointed Ido Gur as its new Chief Executive Officer.
- Verb Technology Company, Inc. VERB shares fell 48.7% to $0.1990 after the company priced its $7.2 million underwritten public offering of common stock.
- LogicMark, Inc. LGMK fell 41.2% to $0.2149 after the company reported pricing of $5.2 million underwritten public offering priced above market.
- Scilex Holding Company SCLX dropped 36.4% to $6.05.
- Altamira Therapeutics Ltd. CYTO fell 26.2% to $3.69 after the company provided an update on its clinical trials with Bentrio. The COVAMID study did not reach the primary efficacy endpoint.
- Cassava Sciences, Inc. SAVA fell 22.4% to $28.28 after the company reported top-line clinical results in Phase 2 study evaluating simufilam in Alzheimer's disease.
- MicroCloud Hologram Inc. HOLO dipped 21.2% to $10.21.
- Tenax Therapeutics, Inc. TENX dropped 19.7% to $2.0550. Tenax Therapeutics recently announced a 1-for-20 reverse stock split.
- Cadrenal Therapeutics, Inc. CVKD fell 17.6% to $3.23.
- Qilian International Holding Group Limited QLI dropped 15% to $1.08.
- Kiromic BioPharma, Inc. KRBP dropped 14.8% to $0.23.
- Allarity Therapeutics, Inc. ALLR fell 14.6% to $0.2510.
- FLJ Group Limited FLJ dropped 12.4% to $2.33.
- Soluna Holdings, Inc. SLNH fell 9.6% to $0.47.
- Sorrento Therapeutics, Inc. SRNE dipped 8.9% to $0.9747. Sorrento released unblinded Phase 1b study data of OVYDSO in COVID patients.
- ERYTECH Pharma S.A. ERYP dropped 7% to $0.53.
Also Check This Out Bitcoin Nears This Key Level; Threshold Emerges As Top Gainer
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in